Physician profile
Lynn Milliman
NPI 1790824498
$1,266.78
in general payments reported to CMS, 2019-2025
12 companies · $390 in 2025
The $390 reported for 2025 was more than what 81% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $72.97 · 2022: $261 · 2023: $297 · 2024: $246 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $426.97 | 2023-2025 | Veozah, Myrbetriq |
| Evofem Biosciences, INC. | $208.78 | 2022-2024 | Phexxi |
| Abbvie INC. | $202.34 | 2021-2023 | |
| Mindray Ds USA, INC. | $177.56 | 2025 | Te7 Max, Te X |
| Pfizer INC. | $128.97 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $23.38 | 2024 | Gemtesa |
| Sage Therapeutics, LLC | $20.00 | 2025 | Zurzuvae |
| Insulet Corporation | $19.82 | 2025 | Omnipod |
| Smith+Nephew, INC. | $19.81 | 2024 | Pico 7 |
| Merck Sharp & Dohme LLC | $13.76 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Agile Therapeutics, INC. | $13.28 | 2023 | Twirla |
| Lupin INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Milliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.